Novelion Therapeutics Inc (NVLNF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 130,432 | 138,438 | 13,574 | 0 | 0 |
| Cost of Goods | 59,697 | 77,220 | 5,971 | N/A | N/A |
| Gross Profit | 70,735 | 61,218 | 7,603 | N/A | N/A |
| Operating Expenses | 121,499 | 148,236 | 45,280 | 23,345 | 3,829 |
| Operating Income | -50,067 | -86,798 | -36,706 | -23,345 | -3,829 |
| Interest Expense | 50,498 | 39,037 | 2,960 | -277 | -113 |
| Other Income | -6,163 | -292 | -12,739 | 81 | -481 |
| Pre-tax Income | -106,728 | -126,127 | -52,405 | -22,987 | -4,197 |
| Income Tax | 1,599 | 583 | 465 | 22 | -192 |
| Net Income Continuous | -108,327 | -126,710 | -52,870 | -23,009 | -4,005 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -66 |
| Net Income | $-108,327 | $-126,710 | $-52,870 | $-23,009 | $-4,071 |
| EPS Basic Total Ops | -5.76 | -6.81 | -4.69 | -2.20 | -0.40 |
| EPS Basic Continuous Ops | -5.76 | -6.81 | -4.69 | -2.20 | -0.40 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | -0.01 |
| EPS Diluted Total Ops | -5.76 | -6.81 | -4.69 | -2.20 | -0.40 |
| EPS Diluted Continuous Ops | -5.76 | -6.81 | -4.69 | -2.20 | -0.40 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | -0.01 |
| EPS Diluted Before Non-Recurring Items | -5.76 | -6.81 | -12.18 | -2.45 | -2.15 |
| EBITDA(a) | $-20,116 | $-59,696 | $-34,308 | $-22,769 | $-2,938 |